Bayer gifts modern knowledge in some unspecified time in the future of oncology portfolio at the 2023 ASCO Annual Meeting

25

Might per chance

2023

Summary

Bayer continues to apartment advancing prostate cancer care from early to metastatic stage with darolutamide knowledge in non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), and radium-223 dichloride knowledge in metastatic castration-resistant prostate cancer (mCRPC) / Confirming Bayer’s investment in Precision Oncology, larotrectinib knowledge offered at ASCO display lengthy-term efficacy and security in sufferers with tropomyosin receptor kinase (TRK) fusion lung and thyroid cancer, as successfully as to knowledge from investigator-initiated analysis in pediatric sufferers with newly identified childish fibrosarcoma (IFS)